Developer docs
API playgroundTry for free, no card

Search company profiles

Exhalix

Full company profile

uuid0006dbv

Namestring
Exhalix
Legal namestring
Exhalix LLC
Websiteurl
exhalix-llc.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Exhalix LLC is a privately held, pre-commercial medical device company developing proprietary hydrogen sulfide (H2S)-based diagnostic and therapeutic technologies for microvascular health. Its portfolio comprises four core technologies: TAGS™, a non-invasive transdermal diagnostic device that measures endogenous H2S emission rates from the skin surface in under 15 minutes to detect peripheral artery disease (PAD); HEALS™, a topical therapeutic device delivering controlled exogenous H2S to chronic wounds using patented electroactive coating technology with dose control to within 10% of target (1-250 nmol/dose); ReLIS™, an implantable device extending the platform to disadvantaged surgical wounds; and Genie:S™, an on-demand, in-situ H2S synthesis and delivery platform. Pre-clinical studies in Sprague-Dawley and Zucker Diabetic rat models have demonstrated strong revascularization, reperfusion rate, and tissue recovery outcomes.

The company targets vascular surgeons, podiatrists, and the broader healthcare ecosystem treating patients with PAD, chronic limb-threatening ischemia (CLTI), and diabetic chronic wounds—an addressable market of more than 6.5 million Americans with combined healthcare costs exceeding $21 billion. The business model is hardware sales of medical devices to enterprise healthcare buyers, but all products remain investigational (TAGS™) or in preclinical animal studies (HEALS™, ReLIS™) pending FDA clearance. Revenue is currently zero, with funding sourced almost entirely from non-dilutive NIH Small Business Innovation Research (SBIR) grants across multiple institutes (NIGMS, NHLBI, NIA, NCATS, NIDDK) and an NSF award totaling $269,999 in 2016. Distribution occurs through clinical partnerships—primarily with UNM School of Medicine and Texas A&M College of Veterinary Medicine—rather than commercial channels. The company is founder-led, with Reza Shekarriz (Founder/CEO, PhD from WSU, post-doc at Johns Hopkins, 25 years of R&D experience) and Robert Beckius (Director of Engineering, 20+ years of device commercialization), operating with 1-10 employees from Albuquerque, NM.

Short descriptiontext

Exhalix LLC is a pre-commercial medical device company developing proprietary hydrogen sulfide (H2S)-based diagnostic and therapeutic devices for peripheral artery disease, chronic wounds, and microvascular health, serving vascular surgeons, podiatrists, and diabetic patients through clinical research partnerships pending FDA clearance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAlbuquerque, United States
HQ citystring
Albuquerque
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microvascular health diagnostics, peripheral artery disease, chronic wound therapy, hydrogen sulfide sensors, vascular medical devices
Industry3 codes
PRIMARYHLAHAFAK
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Vascular Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Revenue from sale of diagnostic devices (TAGS™) and therapeutic devices (HEALS™, ReLIS™) for peripheral artery disease and chronic wound treatment. Company is currently in pre-commercial stage with investigational devices undergoing clinical validation for FDA clearance.

exhalix-llc.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1TAGS™
Description

Non-invasive diagnostic device that measures transdermal hydrogen sulfide for evaluation of lower extremity vascular health and diagnosis of peripheral artery disease (PAD).

exhalix-llc.com
+3 more records
Core offering1 text field

Exhalix develops non-invasive diagnostic and minimally invasive therapeutic medical devices for the detection and treatment of lower extremity microvascular disease. Its TAGS™ device measures transdermal hydrogen sulfide (H2S) emission from skin to detect peripheral artery disease (PAD), while HEALS™ and ReLIS™ deliver controlled, localized H2S therapy to chronic and surgical wounds using proprietary electroactive coating technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Pre-clinical data from Sprague-Dawley (SD) and Zucker Diabetic (ZDF) rats show strong revascularization (Vessel Density), reperfusion rate, and tissue recovery even at highly ischemic conditions
+1 more record
Product overview1 text field

Exhalix develops a portfolio of medical diagnostic and therapeutic products centered on hydrogen sulfide (H2S) technology for microvascular health. The core offerings include: TAGS™ — a non-invasive transdermal diagnostic device that measures H2S emission rates to detect peripheral artery disease; HEALS™ — a topical therapeutic device for chronic wound healing via localized H2S delivery; ReLIS™ — an implantable device for disadvantaged surgical wounds; and Genie:S™ — a platform technology for additional H2S applications. The company employs trace-level gas sensors, microfluidic systems, and microelectronic devices, with electroactive coatings using solid-state metal sulfide technology for controlled H2S synthesis and delivery.

Product and service4 records
1TAGS™ (Transdermal Analyte Gas Sensing)
CategoryVascular Diagnostics
Description

A non-invasive diagnostic device that measures transdermal hydrogen sulfide (H2S) emission rate from the skin surface of the lower extremities in under 15 minutes to evaluate vascular health and detect peripheral artery disease (PAD). Intended for healthcare providers (vascular surgeons, podiatrists, wound care specialists) and currently limited by U.S. Federal law to investigational use pending FDA clearance.

2HEALS™ (Hemodynamic and Endothelial Activation by Localization of Sulfides)
CategoryWound Care Therapeutics
Description

A topical medical device for chronic wound application that locally delivers hydrogen sulfide to wounded tissue using patented electroactive coating technology and solid-state metal sulfide coatings, accelerating revascularization and wound healing. Aimed at diabetic and vascular chronic wound patients treated by wound care specialists and vascular surgeons; currently in preclinical development.

3ReLIS™ (Repair by Local Infusion of Sulfides)
CategoryImplantable Surgical Therapeutics
Description

An implantable therapeutic device built on the same electroactive coating platform as HEALS that delivers sulfides directly to disadvantaged, ischemic surgical wounds to support revascularization and tissue recovery. Intended for surgical patients at risk of wound complications; currently in preclinical animal studies with the UNM School of Medicine.

4Genie:S™ Platform
CategoryTherapeutic Platform Technology
Description

Platform technology for on-demand, in-situ hydrogen sulfide synthesis and delivery using electrolytic technology and solid-state metal sulfide coatings, intended to support additional therapeutic applications of H2S delivery beyond chronic and surgical wounds.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on development of bandage-like device that delivers hydrogen sulfide gas directly to wounds to improve healing. Texas A&M researchers working with Exhalix on preclinical development of wound treatment technology using specialized coating to generate controlled H2S locally at wound site.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing clinical partnership for development and testing of TAGS™, HEALS™, and ReLIS™ technologies. Multiple NIH-funded collaborations including Phase I SBIR grants for prototype development, clinical trials, and productization. UNM vascular surgeons and researchers contributing to research on H2S signaling molecule and clinical validation studies.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Spun out from Exhalix LLC in January 2025 for commercialization of TAGS™ technology. Represents dedicated entity for diagnostic device commercialization separate from therapeutic development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Sulfagenix
TypeDirect peer
Description

Clinical-stage biotech developing hydrogen sulfide (H2S) donor therapeutics for cardiovascular and other diseases. Closest scientific peer to Exhalix's H2S-based therapeutic approach, although Sulfagenix uses systemic drug delivery while Exhalix uses device-based local delivery.

2CardieX (parent of AtCor Medical)
TypeDirect peer
Description

Develops non-invasive central blood pressure and arterial stiffness assessment devices (SphygmoCor, Conneqt) for cardiovascular disease diagnosis including PAD. Direct functional peer to TAGS™ as a non-invasive vascular diagnostic.

TypeDirect peer
Description

Develops EndoPAT® for non-invasive endothelial function assessment, directly relevant to Exhalix's core thesis that endothelial dysfunction (H2S-related) is a diagnostic and therapeutic target. Both companies address vascular health via novel biomarkers.

TypeBroad incumbent
Description

Leading commercial-stage wound care company with Apligraf® (skin substitute) and other regenerative products. Represents the established wound healing market that HEALS™ would compete in once approved; comparable business model (medical device + biologics for wound healing) but much larger scale and established reimbursement.

TypeBroad incumbent
Description

Diversified medical device company with significant wound care and regenerative tissue franchise (Integra Dermal Regeneration Template). Competes in the same chronic wound and surgical wound healing markets targeted by HEALS™ and ReLIS™.

TypeBroad incumbent
Description

Commercial-stage wound care and surgical recovery company with EpiFix® (dehydrated amniotic membrane allograft). Direct competitor in advanced chronic wound treatment market; comparable distribution model through wound care clinics and podiatry.

TypeBroad incumbent
Description

Global leader in wound care (Biatain, Comfeel portfolios) and ostomy care. Major incumbent in the chronic wound management market where HEALS™ would compete; provides scale and reimbursement benchmark for wound healing therapeutics.

TypeBroad incumbent
Description

Multinational medical device company with substantial advanced wound management franchise (PICO, ACTICOAT, RENASYS). Major incumbent serving vascular surgeons and wound care clinics that would be the initial call point for HEALS™ and ReLIS™.

TypeBroad incumbent
Description

Global medical products company with major advanced wound care portfolio (AQUACEL, Foam Lite). Direct incumbent in the chronic wound care market and comparable customer base (wound care nurses, podiatrists, vascular surgeons).

TypeBroad incumbent
Description

Large medical device division offering PAD diagnostic and treatment products. Represents the kind of strategic acquirer or competitor that could partner with or compete against Exhalix in the vascular diagnostic space; comparable end customer (vascular specialists) but vastly broader portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exhalix

Vascular Medical Devicesexhalix-llc.com

Exhalix LLC is a pre-commercial medical device company developing proprietary hydrogen sulfide (H2S)-based diagnostic and therapeutic devices for peripheral artery disease, chronic wounds, and microvascular health, serving vascular surgeons, podiatrists, and diabetic patients through clinical research partnerships pending FDA clearance.

What Exhalix does

Exhalix LLC is a privately held, pre-commercial medical device company developing proprietary hydrogen sulfide (H2S)-based diagnostic and therapeutic technologies for microvascular health. Its portfolio comprises four core technologies: TAGS™, a non-invasive transdermal diagnostic device that measures endogenous H2S emission rates from the skin surface in under 15 minutes to detect peripheral artery disease (PAD); HEALS™, a topical therapeutic device delivering controlled exogenous H2S to chronic wounds using patented electroactive coating technology with dose control to within 10% of target (1-250 nmol/dose); ReLIS™, an implantable device extending the platform to disadvantaged surgical wounds; and Genie:S™, an on-demand, in-situ H2S synthesis and delivery platform. Pre-clinical studies in Sprague-Dawley and Zucker Diabetic rat models have demonstrated strong revascularization, reperfusion rate, and tissue recovery outcomes.

The company targets vascular surgeons, podiatrists, and the broader healthcare ecosystem treating patients with PAD, chronic limb-threatening ischemia (CLTI), and diabetic chronic wounds—an addressable market of more than 6.5 million Americans with combined healthcare costs exceeding $21 billion. The business model is hardware sales of medical devices to enterprise healthcare buyers, but all products remain investigational (TAGS™) or in preclinical animal studies (HEALS™, ReLIS™) pending FDA clearance. Revenue is currently zero, with funding sourced almost entirely from non-dilutive NIH Small Business Innovation Research (SBIR) grants across multiple institutes (NIGMS, NHLBI, NIA, NCATS, NIDDK) and an NSF award totaling $269,999 in 2016. Distribution occurs through clinical partnerships—primarily with UNM School of Medicine and Texas A&M College of Veterinary Medicine—rather than commercial channels. The company is founder-led, with Reza Shekarriz (Founder/CEO, PhD from WSU, post-doc at Johns Hopkins, 25 years of R&D experience) and Robert Beckius (Director of Engineering, 20+ years of device commercialization), operating with 1-10 employees from Albuquerque, NM.

Exhalix firmographics

Firmographics
Name
Exhalix
Legal name
Exhalix LLC
Website
https://exhalix-llc.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Exhalix LLC is a pre-commercial medical device company developing proprietary hydrogen sulfide (H2S)-based diagnostic and therapeutic devices for peripheral artery disease, chronic wounds, and microvascular health, serving vascular surgeons, podiatrists, and diabetic patients through clinical research partnerships pending FDA clearance.
Ownership category
akta.pro rank

Exhalix industry classification

Industry
Product category
Vascular Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAK
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Microvascular health diagnostics
  • Peripheral artery disease
  • Chronic wound therapy
  • Hydrogen sulfide sensors
  • Vascular medical devices

Where Exhalix is headquartered

Location

Headquarters

HQ city
Albuquerque
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Exhalix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Medical Device Sales: Revenue from sale of diagnostic devices (TAGS™) and therapeutic devices (HEALS™, ReLIS™) for peripheral artery disease and chronic wound treatment. Company is currently in pre-commercial stage with investigational devices undergoing clinical validation for FDA clearance.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Exhalix product offering

Product offering

Core offering

Exhalix develops non-invasive diagnostic and minimally invasive therapeutic medical devices for the detection and treatment of lower extremity microvascular disease. Its TAGS™ device measures transdermal hydrogen sulfide (H2S) emission from skin to detect peripheral artery disease (PAD), while HEALS™ and ReLIS™ deliver controlled, localized H2S therapy to chronic and surgical wounds using proprietary electroactive coating technology.

Product overview

Exhalix develops a portfolio of medical diagnostic and therapeutic products centered on hydrogen sulfide (H2S) technology for microvascular health. The core offerings include: TAGS™ — a non-invasive transdermal diagnostic device that measures H2S emission rates to detect peripheral artery disease; HEALS™ — a topical therapeutic device for chronic wound healing via localized H2S delivery; ReLIS™ — an implantable device for disadvantaged surgical wounds; and Genie:S™ — a platform technology for additional H2S applications. The company employs trace-level gas sensors, microfluidic systems, and microelectronic devices, with electroactive coatings using solid-state metal sulfide technology for controlled H2S synthesis and delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • TAGS™: Non-invasive diagnostic device that measures transdermal hydrogen sulfide for evaluation of lower extremity vascular health and diagnosis of peripheral artery disease (PAD).
  • HEALS™
  • ReLIS™
  • Genie:S™

Products and services

  • TAGS™ (Transdermal Analyte Gas Sensing) A non-invasive diagnostic device that measures transdermal hydrogen sulfide (H2S) emission rate from the skin surface of the lower extremities in under 15 minutes to evaluate vascular health and detect peripheral artery disease (PAD). Intended for healthcare providers (vascular surgeons, podiatrists, wound care specialists) and currently limited by U.S. Federal law to investigational use pending FDA clearance.
  • HEALS™ (Hemodynamic and Endothelial Activation by Localization of Sulfides) A topical medical device for chronic wound application that locally delivers hydrogen sulfide to wounded tissue using patented electroactive coating technology and solid-state metal sulfide coatings, accelerating revascularization and wound healing. Aimed at diabetic and vascular chronic wound patients treated by wound care specialists and vascular surgeons; currently in preclinical development.
  • ReLIS™ (Repair by Local Infusion of Sulfides) An implantable therapeutic device built on the same electroactive coating platform as HEALS that delivers sulfides directly to disadvantaged, ischemic surgical wounds to support revascularization and tissue recovery. Intended for surgical patients at risk of wound complications; currently in preclinical animal studies with the UNM School of Medicine.
  • Genie:S™ Platform Platform technology for on-demand, in-situ hydrogen sulfide synthesis and delivery using electrolytic technology and solid-state metal sulfide coatings, intended to support additional therapeutic applications of H2S delivery beyond chronic and surgical wounds.

Quantifiable outcome

  • Pre-clinical data from Sprague-Dawley (SD) and Zucker Diabetic (ZDF) rats show strong revascularization (Vessel Density), reperfusion rate, and tissue recovery even at highly ischemic conditions
  • +1 more outcomes

Companies that use Exhalix

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Exhalix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Exhalix partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and major.

  • Texas A&M College of Veterinary Medicine and Biomedical SciencescoreStrategic or Co-development PartnerCollaboration on development of bandage-like device that delivers hydrogen sulfide gas directly to wounds to improve healing. Texas A&M researchers working with Exhalix on preclinical development of wound treatment technology using specialized coating to generate controlled H2S locally at wound site.
  • UNM School of MedicinecoreStrategic or Co-development PartnerLong-standing clinical partnership for development and testing of TAGS™, HEALS™, and ReLIS™ technologies. Multiple NIH-funded collaborations including Phase I SBIR grants for prototype development, clinical trials, and productization. UNM vascular surgeons and researchers contributing to research on H2S signaling molecule and clinical validation studies.
  • TAGS MedicalmajorStrategic or Co-development PartnerSpun out from Exhalix LLC in January 2025 for commercialization of TAGS™ technology. Represents dedicated entity for diagnostic device commercialization separate from therapeutic development.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Exhalix competitors and assessment

Company assessment

Direct peers

  • Sulfagenix: Clinical-stage biotech developing hydrogen sulfide (H2S) donor therapeutics for cardiovascular and other diseases. Closest scientific peer to Exhalix's H2S-based therapeutic approach, although Sulfagenix uses systemic drug delivery while Exhalix uses device-based local delivery.
  • CardieX (parent of AtCor Medical): Develops non-invasive central blood pressure and arterial stiffness assessment devices (SphygmoCor, Conneqt) for cardiovascular disease diagnosis including PAD. Direct functional peer to TAGS™ as a non-invasive vascular diagnostic.
  • Itamar Medical (ZOLL Itamar): Develops EndoPAT® for non-invasive endothelial function assessment, directly relevant to Exhalix's core thesis that endothelial dysfunction (H2S-related) is a diagnostic and therapeutic target. Both companies address vascular health via novel biomarkers.

Broad incumbents

  • Organogenesis: Leading commercial-stage wound care company with Apligraf® (skin substitute) and other regenerative products. Represents the established wound healing market that HEALS™ would compete in once approved; comparable business model (medical device + biologics for wound healing) but much larger scale and established reimbursement.
  • Integra LifeSciences: Diversified medical device company with significant wound care and regenerative tissue franchise (Integra Dermal Regeneration Template). Competes in the same chronic wound and surgical wound healing markets targeted by HEALS™ and ReLIS™.
  • MiMedx: Commercial-stage wound care and surgical recovery company with EpiFix® (dehydrated amniotic membrane allograft). Direct competitor in advanced chronic wound treatment market; comparable distribution model through wound care clinics and podiatry.
  • Coloplast: Global leader in wound care (Biatain, Comfeel portfolios) and ostomy care. Major incumbent in the chronic wound management market where HEALS™ would compete; provides scale and reimbursement benchmark for wound healing therapeutics.
  • Smith+Nephew: Multinational medical device company with substantial advanced wound management franchise (PICO, ACTICOAT, RENASYS). Major incumbent serving vascular surgeons and wound care clinics that would be the initial call point for HEALS™ and ReLIS™.
  • ConvaTec: Global medical products company with major advanced wound care portfolio (AQUACEL, Foam Lite). Direct incumbent in the chronic wound care market and comparable customer base (wound care nurses, podiatrists, vascular surgeons).
  • Abbott Vascular: Large medical device division offering PAD diagnostic and treatment products. Represents the kind of strategic acquirer or competitor that could partner with or compete against Exhalix in the vascular diagnostic space; comparable end customer (vascular specialists) but vastly broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Exhalix social profiles

Digital presence

Exhalix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exhalix leadership team

Management profile

Number of profiles

Profiles2 records

Exhalix subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Exhalix funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exhalix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exhalix

What does Exhalix do?

Exhalix develops non-invasive diagnostic and minimally invasive therapeutic medical devices for the detection and treatment of lower extremity microvascular disease. Its TAGS™ device measures transdermal hydrogen sulfide (H2S) emission from skin to detect peripheral artery disease (PAD), while HEALS™ and ReLIS™ deliver controlled, localized H2S therapy to chronic and surgical wounds using proprietary electroactive coating technology.

Is Exhalix a public or private company?

Exhalix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Exhalix founded?

Exhalix was founded in 2012. It employs 1 to 10 people.

Where is Exhalix based?

Exhalix is headquartered in Albuquerque, United States, in the North America region.

How does Exhalix make money?

One revenue line is on record: medical Device Sales.

Who are Exhalix's main competitors?

Direct peers on record are Sulfagenix, CardieX (parent of AtCor Medical) and Itamar Medical (ZOLL Itamar). Broad incumbents are Organogenesis, Integra LifeSciences, MiMedx, Coloplast, Smith+Nephew, ConvaTec and Abbott Vascular.

Does Exhalix have an API?

No public API is recorded for Exhalix.

What industry is Exhalix in?

Exhalix's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems), with a secondary code of HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals